Xyz historical perspective: Difference between revisions
Jump to navigation
Jump to search
Usama Talib (talk | contribs) |
Preeti Singh (talk | contribs) No edit summary |
||
| Line 9: | Line 9: | ||
===Discovery=== | ===Discovery=== | ||
* | *In 1871, Bilroth, a Prussian-born Austrian surgeon, was the first to described a case of Non- Hodgkin lymphoma, and coined the term malignant lymphoma. | ||
*In 1864, Virchow , a German physician , described lymph node enlargement not related to leukemia as lymphosarcoma a subdivision of aleukimic type of lukemias. | |||
* | *In 1865, Cohnheim, a German-Jewish physician , used the term pseudolukemia to describe all common lymphadenopathy and splenomegaly. <ref {{cite book | last = Pollock | first = Raphael | title = Advanced therapy in surgical oncology | publisher = BC Decker Inc | location = Hamilton, Ontario Lewiston, NY | year = 2008 | isbn = 9781550091267 }}</ref> | ||
*In | *In 1958, [[Denis Parsons Burkitt]], an Irish [[surgeon]], first discovered Burkitt's lymphoma while working in Africa.<ref name="pmid13628987">{{cite journal |author=Burkitt D |title=A sarcoma involving the jaws in African children |journal=The British journal of surgery |volume=46 |issue=197 |pages=218–23 |year=1958 |pmid=13628987|doi=10.1002/bjs.18004619704}}</ref> | ||
*In | *In 1925, Follicular lymphoma was described by Brill and Symmers independently .{{cite journal |vauthors=van Besien K, Schouten H |title=Follicular lymphoma: a historical overview |journal=Leuk. Lymphoma |volume=48 |issue=2 |pages=232–43 |date=February 2007 |pmid=17325883 |doi=10.1080/10428190601059746 |url=}} | ||
*In 1956, Henry Rappaport and his colleagues proposed the Rappaport classification, based on cellular morphology, this became the first widely accepted classification of lymphomas. | |||
== | *In 1966, Armed Forces Institute of Pathology (AFIP) modified the the Rappaport classification in the"Tumors of the Hematopoietic System". | ||
*In 1982, National Cancer Institute introduced the Working Formulation, an amalgamation translating all previous classifications, which defined three grades of non-Hodgkin lymphoma.<ref name="BennettFarrer-Brown1974">{{cite journal|last1=Bennett|first1=MichaelH.|last2=Farrer-Brown|first2=Geoffrey|last3=Henry|first3=Kristin|last4=Jelliffe|first4=A.M.|last5=Gerard-Marchant|first5=R.|last6=Hamlin|first6=Iris|last7=Lennert|first7=K.|last8=Rilke|first8=F.|last9=Stansfeld|first9=A.G.|last10=Van Unnik|first10=J.A.M.|title=CLASSIFICATION OF NON-HODGKIN'S LYMPHOMAS|journal=The Lancet|volume=304|issue=7877|year=1974|pages=405–408|issn=01406736|doi=10.1016/S0140-6736(74)91786-3}}</ref> | |||
*In 1992, Banks first coined the term [[Mantle Cell Lymphoma|mantle cell lymphoma]] (MCL).<ref name="pmid1530105">{{cite journal| author=Banks PM, Chan J, Cleary ML, Delsol G, De Wolf-Peeters C, Gatter K et al.| title=Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. | journal=Am J Surg Pathol | year= 1992 | volume= 16 | issue= 7 | pages= 637-40 | pmid=1530105 | doi= | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1530105 }} </ref> | |||
*In 1994, the Revised European-American Classification of Lymphoid Neoplasms (REAL) classified non Hodgkin's lymphoma, based on immunologic, genetic and clinical characteristics of the disorders in addition to histopathologic characteristics of the tumor cells. | |||
==Landmark Events in the Development of Treatment Strategies== | ==Landmark Events in the Development of Treatment Strategies== | ||
In | *In 1997, FDA approved rituximab, to treat patients with B-cell non-Hodgkin lymphoma that did not responds to other treatments.<ref name="pmid11467356">{{cite journal |vauthors=Grillo-López AJ, White CA, Dallaire BK, Varns CL, Shen CD, Wei A, Leonard JE, McClure A, Weaver R, Cairelli S, Rosenberg J |title=Rituximab: the first monoclonal antibody approved for the treatment of lymphoma |journal=Curr Pharm Biotechnol |volume=1 |issue=1 |pages=1–9 |date=July 2000 |pmid=11467356 |doi= |url=}}</ref> | ||
==Impact on Cultural History== | ==Impact on Cultural History== | ||
Revision as of 17:26, 11 December 2018
|
Xyz Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Xyz historical perspective On the Web |
|
American Roentgen Ray Society Images of Xyz historical perspective |
|
Risk calculators and risk factors for Xyz historical perspective |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Historical Perspective
Discovery
- In 1871, Bilroth, a Prussian-born Austrian surgeon, was the first to described a case of Non- Hodgkin lymphoma, and coined the term malignant lymphoma.
- In 1864, Virchow , a German physician , described lymph node enlargement not related to leukemia as lymphosarcoma a subdivision of aleukimic type of lukemias.
- In 1865, Cohnheim, a German-Jewish physician , used the term pseudolukemia to describe all common lymphadenopathy and splenomegaly.
- In 1925, Follicular lymphoma was described by Brill and Symmers independently .van Besien K, Schouten H (February 2007). "Follicular lymphoma: a historical overview". Leuk. Lymphoma. 48 (2): 232–43. doi:10.1080/10428190601059746. PMID 17325883.
- In 1956, Henry Rappaport and his colleagues proposed the Rappaport classification, based on cellular morphology, this became the first widely accepted classification of lymphomas.
- In 1966, Armed Forces Institute of Pathology (AFIP) modified the the Rappaport classification in the"Tumors of the Hematopoietic System".
- In 1982, National Cancer Institute introduced the Working Formulation, an amalgamation translating all previous classifications, which defined three grades of non-Hodgkin lymphoma.[1]
- In 1992, Banks first coined the term mantle cell lymphoma (MCL).[2]
- In 1994, the Revised European-American Classification of Lymphoid Neoplasms (REAL) classified non Hodgkin's lymphoma, based on immunologic, genetic and clinical characteristics of the disorders in addition to histopathologic characteristics of the tumor cells.
Landmark Events in the Development of Treatment Strategies
- In 1997, FDA approved rituximab, to treat patients with B-cell non-Hodgkin lymphoma that did not responds to other treatments.[3]
Impact on Cultural History
Famous Cases
The following are a few famous cases of disease name:
References
- ↑ Bennett, MichaelH.; Farrer-Brown, Geoffrey; Henry, Kristin; Jelliffe, A.M.; Gerard-Marchant, R.; Hamlin, Iris; Lennert, K.; Rilke, F.; Stansfeld, A.G.; Van Unnik, J.A.M. (1974). "CLASSIFICATION OF NON-HODGKIN'S LYMPHOMAS". The Lancet. 304 (7877): 405–408. doi:10.1016/S0140-6736(74)91786-3. ISSN 0140-6736.
- ↑ Banks PM, Chan J, Cleary ML, Delsol G, De Wolf-Peeters C, Gatter K; et al. (1992). "Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data". Am J Surg Pathol. 16 (7): 637–40. PMID 1530105.
- ↑ Grillo-López AJ, White CA, Dallaire BK, Varns CL, Shen CD, Wei A, Leonard JE, McClure A, Weaver R, Cairelli S, Rosenberg J (July 2000). "Rituximab: the first monoclonal antibody approved for the treatment of lymphoma". Curr Pharm Biotechnol. 1 (1): 1–9. PMID 11467356.